Skip to content
OpenCapital
Get started

Sonoma Pharmaceuticals, Inc. SNOA Q1 2026 Annual earnings

Reported June 16, 2026 · Before market open

Revenue$5.6MMiss by $4.3KDiluted EPS-$0.09Beat by $0.15
Revenue estimate$5.6M
EPS estimate-$0.24

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$5.0M
EPS estimate-$0.30

Versus estimates

Revenue

Q1 2026$5.6MMiss by $4.3K
Q4 2025$4.3MMiss by $1.1MQ3 2025$5.6MBeat by $1.3MQ2 2025$4.0MMiss by $315.0KQ1 2025$3.8MMiss by $685.6KQ4 2024$3.6MMiss by $876.0K

Diluted EPS

Q1 2026-$0.09Beat by $0.15
Q4 2025-$0.35Miss by $0.06Q3 2025-$0.13Beat by $0.18Q2 2025-$0.37Beat by $0.14Q1 2025-$0.15Beat by $0.58Q4 2024-$0.59Beat by $0.21

Ask the moment Sonoma Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Sonoma Pharmaceuticals, Inc. report Q1 2026 earnings?
Sonoma Pharmaceuticals, Inc. (SNOA) reported Q1 2026 earnings on June 16, 2026 before market open.
What were Sonoma Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Sonoma Pharmaceuticals, Inc. reported revenue of $5.6M and diluted EPS of $-0.09 for Q1 2026.
Did Sonoma Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $5.6M by $4.3K. EPS beat the consensus estimate of $-0.24 by $0.15.
How did Sonoma Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 48.1% from $3.8M a year earlier and diluted EPS grew 40.0% from $-0.15.
Where can I find Sonoma Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001683168-26-004975) and the 10-K periodic report (0001683168-26-004871) directly on SEC EDGAR. The filing index links above go to sec.gov.